Sign in
Not yet recruitingPhase 3

KHN939 compared with placebo for inactive thyroid eye disease in China

Tests KHN939 against placebo in Chinese adults with inactive thyroid eye disease.

Key facts

Who runs it
Beijing Kanghong Biological Medicine Co., Ltd.
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
A Phase III Study of KHN939 in Chinese Patients With Moderate-to-Severe Inactive Thyroid Eye Disease
Status
Not yet recruiting
Phase
Phase 3
People taking part
117 people, planned
Started
Aug 2026
Expected to end
Jun 2027
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • KHN939
  • Placebo
Record updated
23 July 2026

Who can take part

Age
18 years to 70 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (16)Hide the full registry criteria

Who can take part

  • Aged 18-70 years (inclusive) at the time of signing the informed consent form (ICF), male or female
  • Weight between 45 kg and 100 kg (inclusive)
  • Diagnosed with moderate-to-severe inactive TED:; proptosis ≥18 mm, accompanied by at least one of the following: (a) eyelid retraction ≥2 mm; (b) moderate to severe soft tissue involvement; (c) intermittent or continuous diplopia; CAS ≤ 2 points in each eye; CAS ≤ 2 in each eye for 6 months prior to screening (based on medical records); or meets all of the following criteria for ≥ 6 months prior to screening (based on patient self-report or medical records): no progression of proptosis, no new-onset or progressive TED-related diplopia, no new-onset inflammatory TED symptoms; The time since initial TED diagnosis is ≥ 2 years and < 10 years prior to screening (documented by patient history or medical records)
  • Female participants of childbearing potential must have a negative serum pregnancy test during screening and agree to use an effective method of contraception from screening until 90 days after the last dose of the study drug. (Note: Women of non-childbearing potential, defined as surgically sterile or postmenopausal, are exempt.)Male participants must agree to use birth control from screening until at least 90 days after the dose of study drug
  • Able to comply with all protocol-required procedures, examinations, and symptom reporting

Who cannot take part

  • Known hypersensitivity to any component of the study drug formulation, or prior hypersensitivity to any monoclonal antibodies
  • Ocular conditions:; Prior or investigator-assessed diagnosis of dysthyroid optic neuropathy (DON) at screening; Corneal involvement in the study eye without improvement after appropriate treatment; Prior orbital radiotherapy or surgery for TED in the study eye (including orbital decompression, strabismus correction, eyelid correction); Requires immediate or planned ophthalmic surgical intervention during the study period; Has any pre-existing ocular condition (e.g., high myopia, anticipated cataract surgery) that, as determined by the investigator, would preclude study participation or complicate the interpretation of study results
  • Prior/concomitant treatments:; Use of oral or intravenous glucocorticoids within 30 days prior to screening; Periorbital/periocular corticosteroid injection within 90 days of screening; Oral or IV non-steroidal immunosuppressants within 90 days of screening; Corticosteroid or non-steroidal immunosuppressant eye drops within 7 days of screening; Received teprotumumab or teprotumumab N01 at any time prior to screening; Received anti-CD20 antibody therapy within 12 months prior to screening; Received anti-interleukin-6 receptor (anti-IL-6R) antibody therapy within 6 months prior to screening; Received any other investigational therapy for TED at any time prior to screening (including, but not limited to, biologics targeting IGF-1R, FcRn, or TSHR); Received any other monoclonal antibody therapy within 90 days prior to screening; Need for selenium or vitamin supplementation for TED treatment from 21 days pre-dose through study end (multivitamins are permitted)
  • Clinically significant ear disease, prior ear surgery, hearing impairment, or abnormal pure-tone audiometry (defined as a mean bone conduction threshold ≥25 dB at 0.5, 1, 2, 4 kHz, or ≥40 dB at any frequency)
  • Positive for HBsAg with HBV-DNA >1000 IU/mL or currently receiving anti-HBV therapy; positive for HIV antibody or HCV antibody; or active syphilis
  • Participation in any drug, vaccine, or device clinical trial within 3 months prior to screening, or currently within follow-up or within 5 half-lives of another study
  • Any other condition deemed by the investigator as inappropriate for study participation
  • Medical history/conditions:; Medical conditions that contraindicate study drug use, including: suspected or confirmed inflammatory bowel disease (IBD), coagulopathy, Cerebrovascular accident (CVA) or transient ischemic attack (TIA) within 180 days, acute myocardial infarction (MI), unstable angina, or CABG/PCI within 180 days, severe arrhythmia, or severe systemic infection; Malignancy (treated or untreated) within 5 years prior to screening, except for the following cured or non-metastatic conditions: cutaneous squamous cell carcinoma (SCC) or basal cell carcinoma (BCC), cervical or prostate carcinoma in situ (CIS), papillary thyroid carcinoma; Uncontrolled diabetes (HbA1c ≥8.0% at screening, or initiation of a new diabetes medication, or a >10% dose adjustment to an existing diabetes medication within 60 days prior to screening); Poorly controlled thyroid function: defined as FT3 or FT4 deviating ≥50% from local laboratory normal range (≥1.5×ULN or ≤0.5×LLN); Uncontrolled hypertension: defined as SBP ≥160 mmHg or DBP ≥100 mmHg; renal artery stenosis; or other evidence of clinically unstable blood pressure; 12-lead ECG with a heart rate <50 or >100 bpm and evidence of active cardiac disease; or any screening ECG abnormality that, in the investigator's opinion, confounds subsequent interpretation, particularly QTcF >450 ms in males or >470 ms in females
  • Laboratory exclusions at screening:; Alanine aminotransferase (ALT) >3 × ULN; Aspartate aminotransferase (AST) >3 × ULN; Serum creatinine(Cr) ≥1.5 × ULN, or glomerular filtration rate (GFR) <30 mL/min/1.73 m² (MDRD formula)
  • Proptosis at Day 1 (pre-dose) that has decreased by ≥2 mm relative to screening
  • Female subjects who are pregnant or lactating

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Thyroid eye disease

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This is a multicenter, randomized, double-masked, placebo-controlled Phase 3 study to evaluate the efficacy, safety, immunogenicity, and population pharmacokinetic (PopPK) characteristics of KHN939 in Chinese patients with moderate-to-severe inactive thyroid eye disease (TED). Approximately 117 participants who meet the study eligibility criteria will be randomized in a 2:1 ratio (stratified by smoking status) to receive 8 infusions of KHN939 or placebo q3W.

The 2 groups in the trial

  • KHN939 20 mg/kgTreatment being tested

    8 infusions of KHN939 q3W for a total of 21 weeks

    Treatment: KHN939

  • PlaceboPlacebo, for comparison

    8 infusions of placebo q3W for a total of 21 weeks

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Multicenter, Randomized, Double-masked, Placebo-Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of KHN939 in the Treatment of Moderate-to-Severe Inactive Thyroid Eye Disease (TED) in China.
Plain-language title
KHN939 compared with placebo for inactive thyroid eye disease in ChinaGenerated from the registry record. The registry title is the official one.
Criteria questions
Built from NCT07720648, who can take part
Record updated
23 July 2026